Luteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis.
Animals
Antitubercular Agents
/ pharmacology
Chemical and Drug Induced Liver Injury
/ etiology
Drug Therapy, Combination
Immunologic Factors
Immunotherapy
/ methods
Isoniazid
/ adverse effects
Luteolin
/ pharmacology
Mice
Mice, Inbred C57BL
Mycobacterium tuberculosis
/ drug effects
Tuberculosis
/ drug therapy
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
09
10
2020
accepted:
16
07
2021
revised:
01
09
2021
pubmed:
21
8
2021
medline:
1
12
2021
entrez:
20
8
2021
Statut:
epublish
Résumé
Tuberculosis (TB) remains a major health problem throughout the world with one third of the population latently infected and ~1.74 million deaths annually. Current therapy consists of multiple antibiotics and a lengthy treatment regimen, which is associated with risk for the generation of drug-resistant Mycobacterium tuberculosis variants. Therefore, alternate host directed strategies that can shorten treatment length and enhance anti-TB immunity during the treatment phase are urgently needed. Here, we show that Luteolin, a plant-derived hepatoprotective immunomodulator, when administered along with isoniazid as potential host directed therapy promotes anti-TB immunity, reduces the length of TB treatment and prevents disease relapse. Luteolin also enhances long-term anti-TB immunity by promoting central memory T cell responses. Furthermore, we found that Luteolin enhances the activities of natural killer and natural killer T cells, both of which exhibit antitubercular attributes. Therefore, the addition of Luteolin to conventional antibiotic therapy may provide a means to avoid the development of drug-resistance and to improve disease outcome.
Identifiants
pubmed: 34415976
doi: 10.1371/journal.ppat.1009805
pii: PPATHOGENS-D-20-02219
pmc: PMC8409628
doi:
Substances chimiques
Antitubercular Agents
0
Immunologic Factors
0
Luteolin
KUX1ZNC9J2
Isoniazid
V83O1VOZ8L
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1009805Subventions
Organisme : NIH HHS
ID : P51 OD011133
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
ACS Omega. 2019 May 29;4(5):9367-9375
pubmed: 31460026
J Biol Chem. 2003 Oct 10;278(41):39443-51
pubmed: 12878608
N Engl J Med. 1998 Jun 4;338(23):1641-9
pubmed: 9614254
PLoS Pathog. 2020 Sep 21;16(9):e1008887
pubmed: 32956412
Front Cell Infect Microbiol. 2020 Mar 24;10:120
pubmed: 32266170
J Infect Dis. 2014 Dec 15;210(12):1928-37
pubmed: 24943726
J Biol Chem. 2014 Jun 6;289(23):16508-15
pubmed: 24711459
Blood. 2010 Mar 4;115(9):1678-89
pubmed: 19903895
PLoS Negl Trop Dis. 2012;6(9):e1767
pubmed: 23029568
Tumour Biol. 2016 May;37(5):6571-9
pubmed: 26638168
J Infect Dis. 2016 Nov 1;214(9):1456-1464
pubmed: 27571906
Microbiologia. 1996 Mar;12(1):9-16
pubmed: 9019139
J Biol Chem. 2014 Nov 28;289(48):33404-11
pubmed: 25315774
J Immunol. 2008 Feb 1;180(3):1729-36
pubmed: 18209070
Chest. 2005 Jul;128(1):116-23
pubmed: 16002924
Bull World Health Organ. 2002;80(6):489-95; discussion 495-500
pubmed: 12132008
Tuberculosis (Edinb). 2009 Dec;89 Suppl 1:S77-80
pubmed: 20006312
J Exp Med. 2001 Dec 17;194(12):1711-9
pubmed: 11748273
Science. 2001 Jul 13;293(5528):248-50
pubmed: 11452114
J Immunol. 2009 Nov 15;183(10):6639-45
pubmed: 19864591
J Immunol. 2012 Jul 15;189(2):897-905
pubmed: 22711885
J Clin Invest. 2003 Jun;111(11):1703-13
pubmed: 12782673
J Exp Med. 2007 Sep 3;204(9):2159-69
pubmed: 17709423
Nat Rev Immunol. 2002 Dec;2(12):982-7
pubmed: 12461571
Science. 2015 Jan 23;347(6220):400-6
pubmed: 25477212
J Infect Dis. 2017 May 1;215(9):1488-1489
pubmed: 28199694
Nature. 1999 Oct 14;401(6754):708-12
pubmed: 10537110
BMJ. 2008 Mar 1;336(7642):484-7
pubmed: 18250104
Curr Mol Med. 2007 May;7(3):327-37
pubmed: 17504117
Front Immunol. 2017 Jun 30;8:739
pubmed: 28713372
J Biol Chem. 2014 Oct 31;289(44):30190-30195
pubmed: 25202011
Clin Vaccine Immunol. 2010 Apr;17(4):618-25
pubmed: 20107011
Cell Host Microbe. 2021 Feb 10;29(2):165-178.e8
pubmed: 33340449
J Immunol. 2004 Jan 1;172(1):130-7
pubmed: 14688318
Front Immunol. 2014 Apr 22;5:180
pubmed: 24795723
Clin Vaccine Immunol. 2015 Mar;22(3):258-66
pubmed: 25589549
N Engl J Med. 2001 Apr 26;344(17):1294-303
pubmed: 11320389
Annu Rev Immunol. 2001;19:93-129
pubmed: 11244032
J Biol Chem. 2012 Jan 6;287(2):1261-8
pubmed: 22110135
Curr Cancer Drug Targets. 2008 Nov;8(7):634-46
pubmed: 18991571
Vaccine. 2015 Jan 1;33(1):85-91
pubmed: 25448107
N Engl J Med. 1999 Oct 14;341(16):1174-9
pubmed: 10519895
Tuberculosis (Edinb). 2013 Mar;93(2):155-66
pubmed: 23332142
Trends Pharmacol Sci. 2004 May;25(5):280-9
pubmed: 15120495
Emerg Infect Dis. 2007 Aug;13(8):1189-94
pubmed: 17953090
J Immunol. 2009 Nov 15;183(10):6296-302
pubmed: 19841189
Nat Rev Immunol. 2012 Jul 13;12(8):581-91
pubmed: 22790178
Mini Rev Med Chem. 2009 Jan;9(1):31-59
pubmed: 19149659
Nat Immunol. 2003 Mar;4(3):225-34
pubmed: 12563257
Nat Immunol. 2007 Apr;8(4):369-77
pubmed: 17351619
Annu Rev Immunol. 2004;22:745-63
pubmed: 15032595
PLoS Pathog. 2011 Nov;7(11):e1002378
pubmed: 22102818
Evid Based Complement Alternat Med. 2015;2015:647832
pubmed: 26113868
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17414-9
pubmed: 17088564
Nat Med. 2011 Sep 04;17(10):1261-8
pubmed: 21892180